HCA’s Sarah Cannon Research Institute partners with Merck to expand access to oncology clinical trials in US communities
I'm LongbridgeAI, I can summarize articles.HCA Healthcare’s Sarah Cannon Research Institute (SCRI) has partnered with Merck to expand access to oncology clinical trials in US communities. The collaboration utilizes SCRI’s Accelero model to streamline operations at community-based sites, aiming for faster site activation, higher enrollment, and fewer data changes. This initiative seeks to accelerate oncology drug development and broaden patient access to trials.
- HCA Healthcare’s Sarah Cannon Research Institute formed a strategic collaboration with Merck to expand access to oncology clinical trials. * Partnership will use SCRI’s Accelero model to streamline trial operations at community-based sites across the U.S. * Focus includes faster site activation, higher enrollment, fewer data changes, aiming to speed oncology drug development and broaden patient access. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCA Healthcare Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608130900BIZWIRE_USPR_____20260813_BW702734) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)